Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Achilles Therapeutics Plc
(NQ:
ACHL
)
0.7300
-0.0100 (-1.35%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Achilles Therapeutics Plc
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
May 22, 2024
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 08, 2024
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
April 04, 2024
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
April 04, 2024
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
February 05, 2024
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
December 18, 2023
Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
November 13, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
October 23, 2023
Via
ACCESSWIRE
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
September 20, 2023
Via
Investor Brand Network
Exposures
Product Safety
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
September 20, 2023
EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 04, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics to Present at Upcoming Conferences
June 12, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 10, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens
May 10, 2023
- New AI module delivers a "Target-to-T cell” approach for revolutionizing the identification and prioritization of targets for personalized antigen approaches -
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
April 25, 2023
Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company’s operations are not affected by the receipt of the Notice
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status
April 25, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
April 17, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights
March 07, 2023
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022
December 06, 2022
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
November 30, 2022
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method
November 22, 2022
- US patent is for an immunotherapy targeting clonal neoantigens identified by the Achilles Clonality Engine (ACE), including vaccine, antibody, and autologous T cell therapy approaches -
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 08, 2022
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy
October 06, 2022
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T Cell Therapies
November 10, 2021
- Secarna's LNAplusTM ASOs have the potential to optimize personalized T cell therapies being developed by Achilles - Secarna's industry-leading antisense oligonucleotide (ASO) platform LNAplusTM...
From
Secarna Pharmaceuticals GmbH & Co. KG
Via
AccessWire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.